Gujarat Themis Biosyn Limited

2%

entory fluctuation be appropriately adjusted, the restated revenue would have reflected a growth of 2%. The Company has navigated through these headwinds successfully, and we are progressing well on ou

12%

ilities, which are being further expanded. Our R&D spend during this fiscal year was approximately 12% of our sales. The additional fermentation capacity that we are building is also well underway in t

Rs. 150.8 crore

explore the global markets with these new products. In FY25, our top line, EBITDA and PAT stood at Rs. 150.8 crores, Rs. 68.8 crores, and Rs. 48.8 crores, respectively. While we reported better gross margins, inve

Rs. 68.8 crore

markets with these new products. In FY25, our top line, EBITDA and PAT stood at Rs. 150.8 crores, Rs. 68.8 crores, and Rs. 48.8 crores, respectively. While we reported better gross margins, investments in skille

Rs. 48.8 crore

ew products. In FY25, our top line, EBITDA and PAT stood at Rs. 150.8 crores, Rs. 68.8 crores, and Rs. 48.8 crores, respectively. While we reported better gross margins, investments in skilled talent pool led to

Rs. 4.48

ol led to pressure on EBITDA margins. The EPS (for each share of face value Re. 1) for the year is Rs. 4.48.” 3 Click to edit Master title style Quarterly Financial Highlights Revenue (Rs. Cr) 42.0 38.

49.8%

.5 37.7 Q4 FY23-24 Q1 FY24-25 Q2 FY24-25 Q3 FY24-25 Q4 FY24-25 EBITDA (Rs. Cr) / Margin (%) 49.8% 47.8% 47.7% 44.3% 20.9 18.6 15.4 18.9 25 20 15 10 5 0 42.5% 16.0 52% 50% 48% 46%

47.8%

7 Q4 FY23-24 Q1 FY24-25 Q2 FY24-25 Q3 FY24-25 Q4 FY24-25 EBITDA (Rs. Cr) / Margin (%) 49.8% 47.8% 47.7% 44.3% 20.9 18.6 15.4 18.9 25 20 15 10 5 0 42.5% 16.0 52% 50% 48% 46% 44%

47.7%

Y23-24 Q1 FY24-25 Q2 FY24-25 Q3 FY24-25 Q4 FY24-25 EBITDA (Rs. Cr) / Margin (%) 49.8% 47.8% 47.7% 44.3% 20.9 18.6 15.4 18.9 25 20 15 10 5 0 42.5% 16.0 52% 50% 48% 46% 44% 42% 40

44.3%

Q1 FY24-25 Q2 FY24-25 Q3 FY24-25 Q4 FY24-25 EBITDA (Rs. Cr) / Margin (%) 49.8% 47.8% 47.7% 44.3% 20.9 18.6 15.4 18.9 25 20 15 10 5 0 42.5% 16.0 52% 50% 48% 46% 44% 42% 40% 38%

42.5%

DA (Rs. Cr) / Margin (%) 49.8% 47.8% 47.7% 44.3% 20.9 18.6 15.4 18.9 25 20 15 10 5 0 42.5% 16.0 52% 50% 48% 46% 44% 42% 40% 38% Q4 FY23-24 Q1 FY24-25 Q2 FY24-25 Q3 FY24-25 Q4 FY24-

52%

Margin (%) 49.8% 47.8% 47.7% 44.3% 20.9 18.6 15.4 18.9 25 20 15 10 5 0 42.5% 16.0 52% 50% 48% 46% 44% 42% 40% 38% Q4 FY23-24 Q1 FY24-25 Q2 FY24-25 Q3 FY24-25 Q4 FY24-25 18 16 1

“No offering of securities of the Company will be made except by means of a statutory offering document containing detailed information about the Company.”

“We plan to target export markets as well, especially the US and Europe.”

“In FY25, our top line, EBITDA and PAT stood at Rs.”

Sub

1

Investor Relations Advisors

1

Sub

Investor Presentation In terms of Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended), we submit herewith the Investors’ Presentation of the Gujarat Themis Biosyn Limited (‘the Company’) with respect to Company’s Business Overview. Further, a copy of the same is also available on the website of the Company, viz., http://www.gtbl.in/ Kindly take the same on record and acknowledge receipt of the same. Thanking you, Yours faithfully, For Gujarat Themis Biosyn Limited Vineet Gawankar Company Secretary and Compliance Officer MUMBAI OFFICE: Themis House, 11/12 Udyog Nagar, S.V Road, Goregaon (West), Mumbai – 400 104 Tel: 91-22-67607080 / 28757836 Fax: 28746621 / 67607019; E-mail: gtblmumbai@gtbl.in Website Address: www.gtbl.in Gujarat Themis Biosyn Limited Investor Presentation Q4 FY2024-25 Click to edit Master title style Disclaimer This presentation has been prepared by Gujarat Themis Biosyn Limited (the “Company” or “GTBL”) solely for

Investor Relations Advisors

Gujarat Themis Biosyn Limited Adfactors PR Pvt. Ltd. Mr. Pradeep Chandan pradeep.chandan@themismedicare.com Mr. Rahul Trivedi Mr. Savli Mangle rahul.trivedi@adfactorspr.com savli.mangle@adfactorspr.com www.gtbl.in www.adfactorspr.com 15